Research Portfolio

About Santhera Pharmaceuticals

Santhera Pharmaceuticals is a Swiss public company with a focused mission to develop and commercialize treatments for rare neuromuscular diseases, exemplified by its long-term dedication to Duchenne muscular dystrophy (DMD). The company's strategy centers on identifying and advancing compounds that address specific pathological mechanisms in these high-need areas. While historically involved with the FDA-approved drug vamorolone for DMD, Santhera's current pipeline and strategic direction emphasize its ongoing commitment to this challenging therapeutic space.

Therapeutic Areas

Other Neuromuscular Diseases Drugs